Current Report Filing (8-k)
03 Avril 2015 - 8:59PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2015
______________
AOXING PHARMACEUTICAL COMPANY, INC.
(Exact name of registrant as specified in its charter)
______________
|
Florida
|
0-24185
|
65-0636168
|
|
(State or Other Jurisdiction
|
(Commission
|
(I.R.S. Employer
|
|
of Incorporation)
|
File Number)
|
Identification No.)
|
444 Washington Blvd., Suite 3338, Jersey City, New Jersey 07310
(Address of Principal Executive Office) (Zip Code)
(646) 367 1747
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The Registrant today issued a press release titled "NYSE MKT Notifies Aoxing Pharmaceutical Company, Inc. that it has Regained Compliance with a Financial Condition Requirement." A copy of the release is filed as an exhibit to this Report.
Item 9.01 Financial Statements and Exhibits
Exhibits
99.1 Press release dated April 3, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
Aoxing Pharmaceutical Company, Inc.
|
| |
|
|
|
Date: April 3, 2015
|
By:
|
/s/ Zhenjiang Yue
Zhenjiang Yue, Chief Executive Officer
|
Exhibit 99.1
NYSE MKT NOTIFIES AOXING PHARMACEUTICAL COMPANY, INC. THAT IT HAS REGAINED COMPLIANCE WITH A FINANCIAL CONDITION REQUIREMENT
JERSEY CITY, NEW JERSEY. April 3, 2015. Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, has received notice from NYSE MKT (the “Exchange”) that Aoxing Pharma has regained compliance with one of the NYSE MKT LLC's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to Section 1003(a)(iv) of the Company Guide referenced in the Exchange’s letter dated October 25, 2013. The Company is no longer considered financially impaired by the Exchange.
NYSE MKT advised Aoxing Pharma that if its financial condition worsens, it could again fall below compliance with Section 1003(a)(iv), at which time NYSE MKT would examine the relationship between the two incidents of noncompliance and re-evaluate Aoxing Pharma's recovery from the first incident. In addition, NYSE MKT reminded Aoxing Pharma that it remains out of compliance with the following sections of the NYSE MKT Company Guide:
|
·
|
Section 1003(a)(i) since it reported stockholders’ equity of less than $2,000,000 at September 30, 2014 and has incurred losses from continuing operations and/or net losses in two of its three most recent fiscal years;
|
|
·
|
Section 1003(a)(ii) since it reported stockholders’ equity of less than $4,000,000 at December 31, 2014 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years; and
|
|
·
|
Section 1003(a)(iii) since it reported stockholders’ equity of less than $6,000,000 at December 31, 2014 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years.
|
Based on the plans of compliance submitted by the Company, the Exchange has granted the Company until April 27, 2015 to regain compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii).
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). For more information, please visit: www.aoxingpharma.com.
CONTACT:
Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com
Aoxing Pharmaceutical Company New (delisted) (AMEX:AXN)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Aoxing Pharmaceutical Company New (delisted) (AMEX:AXN)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
